Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Cancer Type/Condition:  Cervical cancer
Trial Type:  Prevention
Trial Status:  Active
Results 1-16 of 16 for your search:
Start Over
Primary and Secondary Prevention of Human Papillomavirus (HPV) Disease in China
Phase: Phase IV
Type: Prevention
Status: Approved-not yet active
Age: 13 to 15
Sponsor: Other
Protocol IDs: 37207, NCT01021904
Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females
Phase: Phase IV
Type: Prevention
Status: Active
Age: 15 to 25
Sponsor: Pharmaceutical / Industry
Protocol IDs: 109823, 2013-003429-28, NCT01031069
Does the HPV Vaccine Cause the Same Response in Adolescent Kidney and Liver Transplant Patients as in Healthy Controls?
Phase: Phase IV
Type: Prevention
Status: Active
Age: 11 to 17
Sponsor: Other
Protocol IDs: GardasilMerckGomez-Lobo, NCT01101750
Transmission Reduction and Prevention With HPV Vaccination (TRAP-HPV) Study
Phase: Phase IV
Type: Prevention
Status: Active
Age: 18 to 26
Sponsor: Other
Protocol IDs: CIHR-MOP-125949, IIS #38265, NCT01824537
Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 Study
Phase: Phase III
Type: Prevention
Status: Active
Age: 26 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 113621, NCT01190189
The Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 Study
Phase: Phase III
Type: Prevention
Status: Active
Age: 26 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 113618, NCT01249365
Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus Vaccine in Healthy Female Children
Phase: Phase III
Type: Biomarker/Laboratory analysis, Prevention
Status: Active
Age: 4 to 6 and 15 to 25
Sponsor: Pharmaceutical / Industry
Protocol IDs: 115887, 2011-005604-15, NCT01627561
Imiquimod Treatment of CIN Lesions
Phase: Phase III
Type: Biomarker/Laboratory analysis, Prevention, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: METC 13-2-031, NCT02329171
A Phase I Clinical Trial of an HPV Therapeutic Vaccine
Phase: Phase I
Type: Prevention
Status: Active
Age: 18 to 50
Sponsor: NCI, Other
Protocol IDs: 130662, R01CA143130, NCT01653249
Mother - Daughter Initiative (MDI) in Cervical Cancer Prevention
Phase: No phase specified
Type: Health services research, Prevention
Status: Active
Age: 9 to 13
Sponsor: Other
Protocol IDs: 36448, NCT01096134
A Model for Implementation of Cervical Cancer Screening and HPV Vaccination the Emergency Department: a Pilot Study
Phase: No phase specified
Type: Health services research, Prevention, Screening
Status: Active
Age: 18 to 26
Sponsor: Other
Protocol IDs: 33249, NCT01133509
Trial to Evaluate Single- and Double-freeze Cryotherapy in the Prevention of Cervical Neoplasia
Phase: No phase specified
Type: Prevention, Treatment
Status: Active
Age: 25 to 64
Sponsor: Other
Protocol IDs: 649, NCT01145781
Prevent Exposure to Tobacco Smoke at Home [Gesunde Atemluft zu Hause]
Phase: No phase specified
Type: Behavioral study, Prevention
Status: Approved-not yet active
Age: 3 and under
Sponsor: Other
Protocol IDs: Krebshilfe-107539, DM8-IESO02, NCT00647413
The Study of Immunogenicity of Quadrivalent Vaccine Against Human Papilloma Virus (HPV) Types 6, 11, 16, and 18 (HPV-6/11/16/18) in Chronic Kidney Disease (CKD) Patients
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Prevention
Status: Active
Age: 18 to 26
Sponsor: Other
Protocol IDs: 2011/02_Medicine, NCT01298869
Clinic-based Intervention to Promote Cervical Cancer Prevention Behaviors
Phase: No phase specified
Type: Prevention
Status: Active
Age: 18 to 26
Sponsor: Other
Protocol IDs: StepUpToPrevention, NCT02046265
A New Supplement in the Prevention of Cervical Carcinoma
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Prevention
Status: Approved-not yet active
Age: 24 to 48
Sponsor: Other
Protocol IDs: OASIT-K, NCT02263378
Start Over